![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Swissmedic Plans to Concentrate on Adverse Drug Reports from Sponsors
Swissmedic Plans to Concentrate on Adverse Drug Reports from Sponsors
February 2, 2017
Swissmedic said it will prioritize the review of electronic adverse drug reaction reports from sponsors, following a recent increase in submissions.
In the last two years, the agency has noted a significant increase in submissions due to an increase in participation from drugmakers and amendments to the Therapeutic Product Act.
The agency plans to process the increasing number of reports to identify therapeutic risks at an early stage.
Upcoming Events
-
21Oct